Advertisement

Topics

Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results

17:05 EST 8 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Prepares for Q4 2017 FDA Approval and Q1 2018 Commercial Launch Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel phar...

Other Sources for this Article

Aeterna Zentaris Inc.
Michael V. Ward
Chief Executive Officer
IR@aezsinc.com
843-900-3223

NEXT ARTICLE

More From BioPortfolio on "Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...